FindMyKOL
Clinical trialNCT06395402RecruitingPhase 2Interventional

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

SponsorUniversity of IowaEnrollment120Neuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumors
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will: * Undergo Somatostatin Receptor (SSTR) positron emission tomography (PET) imaging, such as a DOTATOC PET/CT scan * Be randomized to receive standard treatment (as per FDA guidelines) or investigational treatment (customized dosing of Lutathera based upon dosimetry) * Undergo blood tests for 4 to 8 weeks after each Lutathera treatment * Complete patient reported outcome questionnaires * Visit the clinic for follow-up about every 8 weeks.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Holden Comprehensive Cancer Center at the University of Iowa

    Iowa City, Iowa, United States

    David Bushnell, MDJanet Pollard, MDKristin Plichta, MD, PhDMichael Graham, MD, PhDParren McNeely, MDStephen Graves, PhDYusuf Menda, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lutetium Lu 177 dotatate therapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 May 2024
Primary completion
31 Dec 2029
Completion
31 Dec 2029
Last update posted
22 Jul 2025
Registered enrollment
120
Registry id
NCT06395402

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.